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Summary
Objectives To review the effectiveness of smoking cessation
interventions offered to chronic obstructive pulmonary disease (COPD)
patients, and identify barriers to quitting experienced by them, so that a
more effective service can be developed for this group.
Design A rapid systematic literature review comprising computerized
searches of electronic databases, hand searches and snowballing were
used to identify both published and grey literature.
Setting A review of studies undertaken in north-western Europe
(deﬁned as: United Kingdom, Ireland, France, Germany, Benelux and
Nordic countries).
Participants COPD patients participating in studies looking at the
effectiveness of smoking cessation interventions in this patient group, or
exploring the barriers to quitting experienced by these patients.
Method Quantitative and qualitative papers were selected according to
pre-speciﬁed inclusion and exclusion criteria, critically appraised, and
quantitative papers scored against the NICE Levels of Evidence
standardized hierarchy.
Main outcome measure Percentages of successful quitters and
length of quit, assessed by self-report or biochemical analysis. Among
qualitative studies, identiﬁed barriers to smoking cessation had to be
explored.
Results Three qualitative and 13 quantitative papers were ﬁnally
selected. Effective interventions and barriers to smoking cessation were
identiﬁed. Pharmacological support with Buproprion combined with
counselling was signiﬁcantly more efﬁcacious in achieving prolonged
abstinence than a placebo by 18.9% (95% CI 3.6–26.4%). Annual
spirometry with a brief smoking cessation intervention, followed by a
personal letter from a doctor, had a signiﬁcantly higher ≥1 yearabstinence
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1rate at three years among COPD patient smokers, compared to smokers
with normal lung function (P <0.001; z =3.93). Identiﬁed barriers to
cessation included: patient misinformation, levels of motivation, health
beliefs, and poor communication with health professionals.
Conclusion Despite the public health signiﬁcance of COPD, there is a
lack of high-quality evidence showing which smoking cessation support
methods work for these patients. This review describes three effective
interventions, as well as predictors of quitting success that service
providers could use to improve quit rates in this group. Areas that would
beneﬁt from urgent further research are also identiﬁed.
Introduction
The global prevalence of chronic obstructive pul-
monary disease (COPD) is estimated to be
between 4–10% in adults.
1 The World Health
Organization (WHO) estimates it is the ﬁfth
leading cause of mortality in high-income
countries, accounting for 3.5% of deaths, and pre-
dicted to be the third leading cause of death glob-
ally by 2030.
2 COPD patients are prone to acute
exacerbations, often requiring hospitalization.
These episodes signiﬁcantly reduce quality of
life for patients with severe COPD, estimated to
be four times worse than for severe asthmatics.
3
The societal costs of the disease are high. In
2003, there were 41,300 per 100,000 population
lost work days in the European Union due to
COPD, resulting in an annual productivity loss
of E28.5 billion.
4 Interventions that contribute
to delaying disease progression, reduce
co-morbidities or prevent acute exacerbations are
likely to be cost-effective from all perspectives.
5
Although incurable, COPD progression can be
slowed by not smoking and disease management
guidance recommends smoking cessation be
offered to all patients.
6–8However, recommended
brief interventions are based on evidence from
smokers in general, not COPD patients, and quit
rates remain poor among this group.
9,10
An evidence review from 2003, found COPD
patients could achieve long-term cessation using a
combination of pharmacological and psychosocial
interventions, though what kind of psychosocial
intervention was not described.
11,12 The purpose
of this paper is to build on this review by assessing
new evidence in order to develop a more effective
smoking cessation service that demonstrates
improved quit rates in this patient group.
Method
The primary research question sought to ascertain
which smoking cessation interventions are effec-
tive, and to identify any factors that COPD
patients perceive as barriers to quitting. Studies
were identiﬁed through computerized searches
(undertaken February 2010) of the following data-
bases: MEDLINE, CINAL, PsychInfo, EMBASE,
and The Cochrane Collaboration. Search restric-
tions included: English language publications,
year 2003 onwards and research undertaken on
human subjects and adults only. The following
search terms were used: Chronic Obstructive Pul-
monary Disease; COPD; Chronic Obstructive
Airways Disease; Emphysema; Chronic Bronchi-
tis; Chronic Obstructive Bronchitis; Chronic
Airﬂow Limitation; Chronic Airﬂow Obstruction;
Chronic Airways Obstruction; Non-reversible
Obstructive Airways Disease; Alpha-1 trypsin;
smoking cessation; quit/give-up/stop smoking;
(and combinations). Snowballing, hand searches
and consulting local expert stakeholders were
also used to locate unpublished studies or other
‘grey literature’. This identiﬁed 534 papers
(Figure 1).
Selection of papers for detailed review was
based on titles, keywords and abstracts: studies
had either to describe a smoking cessation inter-
vention (intervention studies), or to explore atti-
tudes towards smoking cessation or predictors of
smoking success (descriptive studies).
Shortlisted papers were read in full. Study par-
ticipants had to have a medical or suspected diag-
nosis of COPD (according to American or British
Thoracic Societies, European Respiratory Society
Guidelines, GOLD criteria, or physician diag-
nosed). Outcomes had to include percentages of
J R Soc Med Sh Rep 2011;2:78. DOI 10.1258/shorts.2011.011089
Journal of the Royal Society of Medicine Short Reports
2
and Anna L Hansell
for their constructive
comments and
feedback
Reviewer
Michael Kellysuccessful quitters and length of quit, assessed by
self-report or biochemical analysis. Among quali-
tative studies, identiﬁed barrierstosmoking cessa-
tion were of interest. To promote applicability of
ﬁndings to a UK population, only studies under-
taken in north-western Europe (deﬁned as:
United Kingdom and Ireland, France, Germany,
the Benelux, and Nordic countries) were included,
as these health systems tend to be similar. Case
reports, case series without qualitative ﬁndings,
and studies which did not exclusively look at
COPD or related respiratory conditions (e.g.
emphysema) were excluded.
Abstracts were then reviewed, and full-text
papers were analysed using the Critical Appraisal
Skills Programme framework. Intervention
studies were assigned a rank using the National
Institute for Health and Clinical Excellence
(NICE) Levels of Evidence hierarchy.
13 Interven-
tion categories were determined once papers had
been found and reviewed.
Results
A total of 16 eligible papers describing 14 studies
ﬁnally contributed to this review (Tables 1 and 2).
These described three types of intervention and
four barriers to smoking cessation.
Pharmacological interventions
A randomized trial found Buproprion combined
with smoking cessation counselling was signiﬁ-
cantly more efﬁcacious in achieving prolonged
smoking abstinence than a placebo by 18.9%
(95% CI 3.6–26.4%).
14 The difference between
the Nortriptyline and placebo groups was insig-
niﬁcant, but the former was signiﬁcantly more
likely to discontinue medication due to adverse
events (24% vs. 9%; P <0.01). A separate, under-
powered study found no signiﬁcant difference of
efﬁcacy between a placebo and either Nortripty-
line (RR =1.5; 95% CI 0.8–2.9) or Buproprion
(RR = 1.6; 95% CI 0.8–3.0), respectively, though
Nortriptyline was associated with higher costs
due to increased healthcare visits and absenteeism
from work.
15 From a societal perspective, Bupro-
prion seems more cost-effective of the three
options at E1368 (95% CI E193–5260).
A randomized study investigating the effect of
nurse-conducted smoking cessation interventions
coupled with nicotine replacement therapy (NRT)
found sustained abstinence from week two to 12
was signiﬁcantly higher in those receiving NRT
(OR =2.88; 95% CI 1.34–6.16) compared to those
receiving the placebo treatment.
16 The study
found no statistically signiﬁcant difference
between those receiving low or high support,
though this could be a Type II error as each trial
arm failed to achieve the minimum sample size.
Also, many patients who did not attend their
ﬁnal appointment were followed up by phone,
meaning a biochemical veriﬁcation of their
smoking status was not possible.
Confrontation with spirometry
Spirometry interventions were assessed in two
studies. Low- and high-intensity confrontational
counselling including spirometry was signiﬁ-
cantly more effective than usual care at ﬁve
weeks follow-up. At six months there was only a
signiﬁcant difference between the high-intensity
and usual care groups (OR = 3.24; 95% CI 1.40–
7.49), and at 52 weeks there was no difference
between anyof the groups.
17,18 Annual spirometry
and brief smoking cessation advice followed by a
personal letter from the physician had a signiﬁ-
cantly higher self-reported ≥ 1-year abstinence
rate at three years among COPD smokers,
Figure 1
Identiﬁcation and selection of papers for review
J R Soc Med Sh Rep 2011;2:78. DOI 10.1258/shorts.2011.011089
Effective smoking cessation interventions for COPD patients: a review of the evidence
3T
a
b
l
e
1
I
n
c
l
u
d
e
d
i
n
t
e
r
v
e
n
t
i
o
n
s
t
u
d
i
e
s
R
a
n
k
s
e
t
t
i
n
g
P
a
r
t
i
c
i
p
a
n
t
s
1
T
y
p
e
o
f
s
u
p
p
o
r
t
F
o
l
l
o
w
-
u
p
O
u
t
c
o
m
e
(
i
n
c
l
u
d
i
n
g
l
e
n
g
t
h
o
f
q
u
i
t
)
Q
u
i
t
s
,
n
(
%
)
A
u
t
h
o
r
1
–
N
e
s
t
e
d
i
n
m
u
l
t
i
c
e
n
t
r
e
S
M
O
K
E
R
C
T
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
M
o
d
e
r
a
t
e
t
o
s
e
v
e
r
e
C
O
P
D
p
a
t
i
e
n
t
s
a
g
e
d
4
0
–
7
5
y
e
a
r
s
I
n
t
e
r
v
e
n
t
i
o
n
I
1
1
1
E
x
i
s
t
i
n
g
M
i
n
i
m
a
l
I
n
t
e
r
v
e
n
t
i
o
n
S
t
r
a
t
e
g
y
f
o
r
l
u
n
g
p
a
t
i
e
n
t
s
(
L
M
I
S
)
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
p
r
o
g
r
a
m
m
e
:
i
n
d
i
v
i
d
u
a
l
c
o
u
n
s
e
l
l
i
n
g
a
n
d
t
e
l
e
p
h
o
n
e
c
o
n
t
a
c
t
s
(
1
8
0
m
i
n
t
o
t
a
l
)
+
u
s
e
o
f
p
a
i
d
-
f
o
r
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
i
n
t
e
r
v
e
n
t
i
o
n
i
f
p
a
t
i
e
n
t
-
r
e
q
u
e
s
t
e
d
1
y
e
a
r
C
o
n
t
i
n
u
o
u
s
a
b
s
t
i
n
e
n
c
e
b
y
<
2
0
n
g
/
m
L
s
a
l
i
v
a
c
o
t
i
n
i
n
e
l
e
v
e
l
s
%
(
9
a
n
d
1
9
)
s
t
a
t
e
d
i
n
a
b
s
t
r
a
c
t
b
u
t
n
o
t
v
e
r
i
ﬁ
a
b
l
e
f
r
o
m
b
o
d
y
o
f
p
a
p
e
r
C
h
r
i
s
t
e
n
h
u
s
z
e
t
a
l
.
2
6
I
n
t
e
r
v
e
n
t
i
o
n
I
I
1
1
4
S
t
o
p
s
m
o
k
i
n
g
s
t
r
a
t
e
g
y
(
S
S
T
)
:
g
r
o
u
p
a
n
d
i
n
d
i
v
i
d
u
a
l
c
o
u
n
s
e
l
l
i
n
g
a
n
d
t
e
l
e
p
h
o
n
e
c
o
n
t
a
c
t
s
(
5
9
5
m
i
n
t
o
t
a
l
)
+
u
s
e
o
f
f
r
e
e
B
u
p
r
o
p
i
o
n
2
–
P
r
i
m
a
r
y
h
e
a
l
t
h
c
a
r
e
c
e
n
t
r
e
,
S
w
e
d
e
n
C
O
P
D
p
a
t
i
e
n
t
s
,
4
0
–
7
0
y
e
a
r
s
I
n
t
e
r
v
e
n
t
i
o
n
3
0
S
p
e
c
i
ﬁ
c
a
l
l
y
d
e
s
i
g
n
e
d
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
p
r
o
g
r
a
m
m
e
a
n
d
p
r
o
g
r
a
m
m
e
s
f
o
r
p
h
y
s
i
c
a
l
a
c
t
i
v
i
t
y
a
n
d
d
i
e
t
1
y
e
a
r
C
O
v
e
r
i
ﬁ
e
d
(
≤
6
p
p
m
)
a
t
1
y
e
a
r
9
(
4
7
.
4
)
F
a
¨
s
s
b
e
r
g
N
o
r
r
h
a
l
l
e
t
a
l
.
3
2
H
e
a
l
t
h
y
s
m
o
k
e
r
s
,
4
0
–
7
0
y
e
a
r
s
C
o
n
t
r
o
l
1
8
S
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
p
r
o
g
r
a
m
m
e
o
n
l
y
3
(
1
8
.
0
)
1
–
4
3
G
P
p
r
a
c
t
i
c
e
s
,
N
i
j
m
e
n
g
e
n
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
C
O
P
D
p
a
t
i
e
n
t
s
>
3
5
y
e
a
r
s
,
r
e
c
o
r
d
e
d
I
C
P
D
c
o
d
e
R
9
5
/
9
6
m
e
d
i
c
a
t
i
o
n
,
≥
2
s
c
r
i
p
t
s
f
o
r
i
n
h
a
l
e
d
a
n
t
i
-
i
n
ﬂ
a
m
m
a
t
o
r
i
e
s
i
n
p
a
s
t
y
e
a
r
I
n
t
e
r
v
e
n
t
i
o
n
2
4
4
P
a
t
i
e
n
t
s
i
n
v
i
t
e
d
f
o
r
c
o
n
t
r
o
l
v
i
s
i
t
,
w
h
e
r
e
g
i
v
e
n
b
o
o
k
l
e
t
a
n
d
v
i
d
e
o
p
l
u
s
a
l
l
o
c
a
t
e
d
t
o
g
r
o
u
p
s
:
1
–
‘
P
r
e
p
a
r
e
r
s
’
:
i
n
f
o
o
n
c
o
p
i
n
g
w
i
t
h
q
u
i
t
t
i
n
g
b
a
r
r
i
e
r
s
+
N
R
T
i
n
f
o
(
a
c
c
.
n
i
c
o
t
i
n
e
d
e
p
e
n
d
e
n
c
e
s
e
v
e
r
i
t
y
)
;
2
–
‘
C
o
n
t
e
m
p
l
a
t
o
r
s
’
:
i
n
v
i
t
e
d
a
g
a
i
n
2
w
e
e
k
s
l
a
t
e
r
a
n
d
w
h
e
n
d
e
ﬁ
n
e
d
‘
p
r
e
p
a
r
e
r
s
’
,
q
u
i
t
d
a
t
e
m
e
e
t
i
n
g
s
e
t
+
f
o
l
l
o
w
-
u
p
v
i
s
i
t
s
p
l
a
n
n
e
d
;
3
–
N
o
t
w
i
l
l
i
n
g
t
o
q
u
i
t
:
r
e
c
e
i
v
e
d
i
n
f
o
r
e
g
a
r
d
i
n
g
a
d
v
a
n
t
a
g
e
s
o
f
q
u
i
t
t
i
n
g
6
m
o
n
t
h
s
S
e
l
f
-
r
e
p
o
r
t
e
d
p
o
i
n
t
p
r
e
v
a
l
e
n
c
e
a
t
6
m
o
n
t
h
s
o
f
a
b
s
t
i
n
e
n
c
e
i
n
l
a
s
t
7
d
a
y
s
3
9
(
1
6
.
0
)
H
i
l
b
e
r
i
n
k
e
t
a
l
.
2
5
C
o
n
t
r
o
l
1
4
8
U
s
u
a
l
c
a
r
e
b
y
2
2
G
P
p
r
a
c
t
i
c
e
s
u
s
i
n
g
t
h
e
M
i
n
i
m
a
l
I
n
t
e
r
v
e
n
t
i
o
n
S
t
r
a
t
e
g
y
(
M
I
S
)
,
a
s
t
a
g
e
-
b
a
s
e
d
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
i
n
t
e
r
v
e
n
t
i
o
n
f
o
r
G
P
s
1
3
(
8
.
8
)
1
–
P
r
i
m
a
r
y
c
a
r
e
,
n
e
a
r
M
a
a
s
t
r
i
c
h
t
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
S
m
o
k
e
r
s
≥
1
0
p
a
c
k
y
e
a
r
s
,
3
0
–
7
5
y
e
a
r
s
,
w
i
t
h
C
O
P
D
p
r
e
v
i
o
u
s
l
y
u
n
d
e
t
e
c
t
e
d
I
n
t
e
r
v
e
n
t
i
o
n
1
1
6
M
e
d
i
u
m
-
i
n
t
e
n
s
i
t
y
i
n
d
i
v
i
d
u
a
l
c
o
u
n
s
e
l
l
i
n
g
b
y
R
N
w
i
t
h
c
o
n
f
r
o
n
t
a
t
i
o
n
o
f
a
b
n
o
r
m
a
l
s
p
i
r
o
m
e
t
r
y
+
N
o
r
t
r
i
p
t
y
l
i
n
e
5
w
e
e
k
s
a
f
t
e
r
T
Q
D
S
e
l
f
-
r
e
p
o
r
t
e
d
a
b
s
t
i
n
e
n
c
e
a
n
d
u
r
i
n
e
c
o
t
i
n
i
n
e
l
e
v
e
l
<
5
0
m
g
/
m
L
5
0
(
4
3
.
1
)
K
o
t
z
e
t
a
l
.
1
7
C
o
n
t
r
o
l
1
1
2
I
n
d
i
v
i
d
u
a
l
c
o
u
n
s
e
l
l
i
n
g
(
c
o
n
v
e
n
t
i
o
n
a
l
h
e
a
l
t
h
e
d
u
c
a
t
i
o
n
a
n
d
p
r
o
m
o
t
i
o
n
)
b
y
R
N
w
i
t
h
n
o
c
o
n
f
r
o
n
t
a
t
i
o
n
+
N
o
r
t
r
i
p
t
y
l
i
n
e
3
5
(
3
1
.
3
)
(
C
o
n
t
i
n
u
e
d
)
J R Soc Med Sh Rep 2011;2:78. DOI 10.1258/shorts.2011.011089
Journal of the Royal Society of Medicine Short Reports
4T
a
b
l
e
1
C
o
n
t
i
n
u
e
d
R
a
n
k
s
e
t
t
i
n
g
P
a
r
t
i
c
i
p
a
n
t
s
1
T
y
p
e
o
f
s
u
p
p
o
r
t
F
o
l
l
o
w
-
u
p
O
u
t
c
o
m
e
(
i
n
c
l
u
d
i
n
g
l
e
n
g
t
h
o
f
q
u
i
t
)
Q
u
i
t
s
,
n
(
%
)
A
u
t
h
o
r
1
–
P
r
i
m
a
r
y
c
a
r
e
,
n
e
a
r
M
a
a
s
t
r
i
c
h
t
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
S
m
o
k
e
r
s
,
3
0
–
7
0
y
e
a
r
s
,
w
i
t
h
p
r
e
v
i
o
u
s
l
y
u
n
d
e
t
e
c
t
e
d
m
i
l
d
–
m
o
d
e
r
a
t
e
C
O
P
D
I
n
t
e
r
v
e
n
t
i
o
n
1
1
6
M
e
d
i
u
m
-
i
n
t
e
n
s
i
t
y
i
n
d
i
v
i
d
u
a
l
c
o
u
n
s
e
l
l
i
n
g
b
y
R
N
w
i
t
h
c
o
n
f
r
o
n
t
a
t
i
o
n
o
f
a
b
n
o
r
m
a
l
s
p
i
r
o
m
e
t
r
y
+
N
o
r
t
r
i
p
t
y
l
i
n
e
5
–
5
2
w
e
e
k
s
a
f
t
e
r
T
Q
D
P
r
o
l
o
n
g
e
d
a
b
s
t
i
n
e
n
c
e
m
e
a
s
u
r
e
d
b
y
u
r
i
n
e
c
o
t
i
n
i
n
e
(
<
5
0
m
g
/
m
L
)
a
t
5
,
2
6
a
n
d
5
2
w
e
e
k
s
1
3
(
1
1
.
2
)
K
o
t
z
e
t
a
l
.
1
8
C
o
n
t
r
o
l
I
1
1
2
I
n
d
i
v
i
d
u
a
l
c
o
u
n
s
e
l
l
i
n
g
(
c
o
n
v
e
n
t
i
o
n
a
l
h
e
a
l
t
h
e
d
u
c
a
t
i
o
n
a
n
d
p
r
o
m
o
t
i
o
n
)
b
y
R
N
w
i
t
h
n
o
c
o
n
f
r
o
n
t
a
t
i
o
n
+
N
o
r
t
r
i
p
t
y
l
i
n
e
1
3
(
1
1
.
6
)
C
o
n
t
r
o
l
I
I
6
8
C
a
r
e
a
s
u
s
u
a
l
,
i
.
e
.
s
t
a
g
e
-
b
a
s
e
d
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
b
y
G
P
4
(
5
.
9
)
2
+
N
e
s
t
e
d
i
n
R
C
T
o
f
C
O
P
D
s
e
l
f
-
m
a
n
a
g
e
m
e
n
t
e
d
u
c
a
t
i
o
n
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
P
u
l
m
o
n
a
r
y
M
e
d
i
c
i
n
e
D
e
p
a
r
t
m
e
n
t
o
u
t
p
a
t
i
e
n
t
s
w
i
t
h
s
t
a
b
l
e
C
O
P
D
,
4
0
–
7
5
y
e
a
r
s
a
n
d
c
u
r
r
e
n
t
s
m
o
k
e
r
s
6
4
T
h
r
e
e
1
5
–
3
0
-
m
i
n
h
o
m
e
-
b
a
s
e
d
c
o
u
n
s
e
l
l
i
n
g
s
e
s
s
i
o
n
s
d
e
l
i
v
e
r
e
d
b
y
p
h
a
r
m
a
c
y
a
s
s
i
s
t
a
n
t
/
R
N
+
N
R
T
o
r
b
u
p
r
i
o
n
i
f
r
e
q
u
e
s
t
e
d
9
m
o
n
t
h
s
S
e
l
f
-
r
e
p
o
r
t
+
s
a
l
i
v
a
c
o
t
i
n
i
n
e
≤
2
0
n
g
/
m
L
8
(
1
2
.
5
)
M
o
n
n
i
n
k
h
o
f
e
t
a
l
.
2
3
1
−
6
p
r
i
m
a
r
y
c
a
r
e
c
e
n
t
r
e
s
,
S
w
e
d
e
n
P
a
t
i
e
n
t
s
w
i
t
h
m
i
l
d
C
O
P
D
1
1
9
I
n
i
t
i
a
l
s
p
i
r
o
m
e
t
r
y
,
b
r
i
e
f
a
d
v
i
c
e
(
<
1
0
m
i
n
s
)
b
y
R
N
,
f
o
l
l
o
w
e
d
u
p
b
y
d
o
c
t
o
r
’
s
l
e
t
t
e
r
i
n
c
.
s
p
i
r
o
m
e
t
r
y
r
e
s
u
l
t
s
a
n
d
s
t
a
n
d
a
r
d
s
t
o
p
s
m
o
k
i
n
g
a
d
v
i
c
e
+
N
R
T
/
B
u
p
r
o
p
r
i
o
n
i
f
c
l
i
e
n
t
s
o
-
w
i
s
h
e
d
A
n
n
u
a
l
s
p
i
r
o
m
e
t
r
y
f
o
l
l
o
w
-
u
p
f
o
r
3
y
e
a
r
s
3
y
e
a
r
s
S
e
l
f
-
r
e
p
o
r
t
e
d
a
b
s
t
i
n
e
n
c
e
p
r
e
v
a
l
e
n
c
e
>
1
y
e
a
r
a
t
3
y
e
a
r
f
o
l
l
o
w
-
u
p
3
0
(
2
5
)
S
t
r
a
t
e
l
i
s
e
t
a
l
.
1
9
S
m
o
k
e
r
s
w
i
t
h
n
o
r
m
a
l
l
u
n
g
f
u
n
c
t
i
o
n
1
6
1
1
2
(
7
)
1
6
5
I
n
v
i
t
e
d
f
o
r
s
p
i
r
o
m
e
t
r
y
a
f
t
e
r
3
y
e
a
r
s
1
5
(
9
)
1
–
S
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
b
y
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
,
S
w
e
d
e
n
P
a
t
i
e
n
t
s
a
g
e
d
4
0
–
6
0
y
e
a
r
s
,
>
8
c
i
g
s
/
d
a
y
w
i
t
h
m
i
l
d
,
m
o
d
e
r
a
t
e
o
r
s
e
v
e
r
e
C
O
P
D
I
n
t
e
r
v
e
n
t
i
o
n
2
4
7
1
y
e
a
r
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
p
r
o
g
r
a
m
m
e
i
n
c
l
u
d
i
n
g
2
-
w
e
e
k
s
i
n
p
a
t
i
e
n
t
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
a
n
d
t
r
a
i
n
i
n
g
s
t
a
y
s
;
p
o
s
t
i
n
t
e
r
v
e
n
t
i
o
n
p
e
r
s
o
n
a
l
a
n
d
t
e
l
e
p
h
o
n
e
c
o
n
t
a
c
t
w
i
t
h
R
N
w
i
t
h
f
e
e
d
b
a
c
k
d
u
r
i
n
g
o
n
e
y
e
a
r
o
f
f
o
l
l
o
w
-
u
p
3
y
e
a
r
s
C
O
-
v
e
r
i
ﬁ
e
d
(
<
8
p
p
m
)
a
b
s
t
i
n
e
n
c
e
>
6
m
o
n
t
h
s
i
n
s
e
l
f
-
r
e
p
o
r
t
e
d
q
u
i
t
t
e
r
s
a
t
1
a
n
d
3
y
e
a
r
s
1
0
6
(
5
2
)
a
t
1
y
e
a
r
;
7
3
(
3
8
)
a
t
3
y
e
a
r
s
S
u
n
d
b
l
a
d
e
t
a
l
.
2
1
C
o
n
t
r
o
l
2
3
1
U
s
u
a
l
c
a
r
e
(
n
o
t
s
p
e
c
i
ﬁ
e
d
)
1
5
(
7
)
a
t
1
y
e
a
r
;
2
0
(
1
0
)
a
t
3
y
e
a
r
s
(
C
o
n
t
i
n
u
e
d
)
J R Soc Med Sh Rep 2011;2:78. DOI 10.1258/shorts.2011.011089
Effective smoking cessation interventions for COPD patients: a review of the evidence
5T
a
b
l
e
1
C
o
n
t
i
n
u
e
d
R
a
n
k
s
e
t
t
i
n
g
P
a
r
t
i
c
i
p
a
n
t
s
1
T
y
p
e
o
f
s
u
p
p
o
r
t
F
o
l
l
o
w
-
u
p
O
u
t
c
o
m
e
(
i
n
c
l
u
d
i
n
g
l
e
n
g
t
h
o
f
q
u
i
t
)
Q
u
i
t
s
,
n
(
%
)
A
u
t
h
o
r
1
–
7
p
u
l
m
o
n
a
r
y
o
u
t
p
a
t
i
e
n
t
c
l
i
n
i
c
s
,
D
e
n
m
a
r
k
C
O
P
D
p
a
t
i
e
n
t
s
≥
1
8
y
e
a
r
s
a
n
d
s
m
o
k
i
n
g
≥
1
c
i
g
/
d
a
y
I
n
t
e
r
v
e
n
t
i
o
n
I
9
5
N
i
c
o
t
i
n
e
s
u
b
l
i
n
g
u
a
l
t
a
b
l
e
t
(
d
o
s
a
g
e
a
c
c
.
s
m
o
k
i
n
g
l
e
v
e
l
s
)
f
o
r
1
2
w
e
e
k
s
+
l
o
w
s
u
p
p
o
r
t
(
4
v
i
s
i
t
s
p
l
u
s
6
p
h
o
n
e
c
a
l
l
s
)
1
y
e
a
r
S
e
l
f
-
r
e
p
o
r
t
e
d
a
n
d
C
O
-
v
e
r
i
ﬁ
e
d
(
<
1
0
p
p
m
)
p
o
i
n
t
p
r
e
v
a
l
e
n
c
e
a
n
d
s
u
s
t
a
i
n
e
d
a
b
s
t
i
n
e
n
c
e
r
a
t
e
s
a
t
6
a
n
d
1
2
m
o
n
t
h
s
1
3
(
1
3
.
7
)
T
ø
n
n
e
s
e
n
e
t
a
l
.
1
6
I
n
t
e
r
v
e
n
t
i
o
n
I
I
9
0
N
i
c
o
t
i
n
e
s
u
b
l
i
n
g
u
a
l
t
a
b
l
e
t
(
d
o
s
a
g
e
a
c
c
.
s
m
o
k
i
n
g
l
e
v
e
l
s
)
f
o
r
1
2
w
e
e
k
s
+
h
i
g
h
s
u
p
p
o
r
t
(
7
v
i
s
i
t
s
p
l
u
s
5
p
h
o
n
e
c
a
l
l
s
)
1
3
(
1
4
.
4
)
C
o
n
t
r
o
l
I
8
8
P
l
a
c
e
b
o
+
l
o
w
s
u
p
p
o
r
t
(
4
v
i
s
i
t
s
p
l
u
s
6
p
h
o
n
e
c
a
l
l
s
)
4
(
4
.
5
)
C
o
n
t
r
o
l
I
I
9
7
P
l
a
c
e
b
o
+
h
i
g
h
s
u
p
p
o
r
t
(
7
v
i
s
i
t
s
p
l
u
s
5
p
h
o
n
e
c
a
l
l
s
)
6
(
6
.
2
)
1
+
R
e
s
e
a
r
c
h
s
e
t
t
i
n
g
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
A
t
r
i
s
k
f
o
r
o
r
w
i
t
h
m
i
l
d
C
O
P
D
,
3
0
–
7
0
y
e
a
r
s
,
≥
1
0
c
i
g
s
/
d
a
y
,
m
o
t
i
v
a
t
e
d
t
o
q
u
i
t
I
n
t
e
r
v
e
n
t
i
o
n
I
8
6
I
n
d
i
v
i
d
u
a
l
f
a
c
e
-
t
o
-
f
a
c
e
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
c
o
u
n
s
e
l
l
i
n
g
(
3
×
2
0
m
i
n
)
a
n
d
p
h
o
n
e
c
a
l
l
s
(
6
×
5
m
i
n
)
+
B
u
p
r
o
p
r
i
o
n
-
S
R
1
y
e
a
r
S
e
l
f
-
r
e
p
o
r
t
e
d
a
n
d
u
r
i
n
e
c
o
t
i
n
i
n
e
-
v
a
l
i
d
a
t
e
d
(
6
0
n
g
/
m
L
c
u
t
-
o
f
f
)
p
r
o
l
o
n
g
e
d
a
b
s
t
i
n
e
n
c
e
m
e
a
s
u
r
e
d
a
t
4
,
1
2
,
2
6
a
n
d
5
2
w
e
e
k
s
1
8
(
2
0
.
9
)
V
a
n
S
c
h
a
y
c
k
e
t
a
l
.
1
5
I
n
t
e
r
v
e
n
t
i
o
n
I
I
8
0
I
n
d
i
v
i
d
u
a
l
f
a
c
e
-
t
o
-
f
a
c
e
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
c
o
u
n
s
e
l
l
i
n
g
(
3
×
2
0
m
i
n
)
a
n
d
p
h
o
n
e
c
a
l
l
s
(
6
×
5
m
i
n
)
+
N
o
r
t
r
i
p
t
y
l
i
n
e
1
6
(
2
0
.
0
)
C
o
n
t
r
o
l
8
9
I
n
d
i
v
i
d
u
a
l
f
a
c
e
-
t
o
-
f
a
c
e
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
c
o
u
n
s
e
l
l
i
n
g
(
3
×
2
0
m
i
n
)
a
n
d
p
h
o
n
e
c
a
l
l
s
(
6
×
5
m
i
n
)
+
p
l
a
c
e
b
o
1
2
(
1
3
.
5
)
1
+
T
h
e
N
e
t
h
e
r
l
a
n
d
s
A
t
r
i
s
k
o
f
/
w
i
t
h
C
O
P
D
,
3
0
–
7
0
y
r
s
,
≥
1
0
c
i
g
s
/
d
a
y
l
a
s
t
y
r
,
m
i
n
.
5
-
y
r
s
m
o
k
e
r
h
i
s
t
o
r
y
I
n
t
e
r
v
e
n
t
i
o
n
I
8
6
B
u
p
r
o
p
r
i
o
n
S
R
f
o
r
1
2
w
e
e
k
s
+
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
c
o
u
n
s
e
l
l
i
n
g
6
m
t
h
s
P
r
o
l
o
n
g
e
d
a
b
s
t
i
n
e
n
c
e
w
e
e
k
4
–
2
6
a
f
t
e
r
T
Q
D
,
a
s
s
e
s
s
e
d
b
y
s
e
l
f
-
r
e
p
o
r
t
+
u
r
i
n
e
c
o
t
i
n
i
n
e
v
a
l
u
e
s
≤
6
0
n
g
/
m
L
1
2
(
2
7
.
3
)
W
a
g
e
n
a
e
t
a
l
.
2
0
0
5
I
n
t
e
r
v
e
n
t
i
o
n
I
I
8
0
N
o
r
t
r
i
p
t
y
l
i
n
e
f
o
r
1
2
w
e
e
k
s
+
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
c
o
u
n
s
e
l
l
i
n
g
1
1
(
2
1
.
2
)
C
o
n
t
r
o
l
8
9
P
l
a
c
e
b
o
+
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
c
o
u
n
s
e
l
l
i
n
g
4
(
8
.
3
)
2
+
R
e
s
e
a
r
c
h
s
e
t
t
i
n
g
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
S
m
o
k
e
r
s
w
i
t
h
C
O
P
D
o
r
c
h
r
o
n
i
c
b
r
o
n
c
h
i
t
i
s
3
8
N
o
n
-
p
h
a
r
m
a
c
o
l
o
g
i
c
s
m
o
k
i
n
g
c
e
s
s
a
t
i
o
n
p
r
o
g
r
a
m
m
e
c
o
n
s
i
s
t
i
n
g
o
f
9
g
r
o
u
p
m
e
e
t
i
n
g
s
(
a
v
e
r
a
g
e
d
u
r
a
t
i
o
n
2
h
)
o
f
8
–
1
0
s
m
o
k
e
r
s
o
v
e
r
6
w
e
e
k
s
r
u
n
b
y
C
O
P
D
n
u
r
s
e
s
p
e
c
i
a
l
i
s
t
a
n
d
r
e
s
e
a
r
c
h
e
r
,
p
l
u
s
a
c
c
e
s
s
t
o
p
e
r
s
o
n
a
l
/
p
h
o
n
e
s
u
p
p
o
r
t
b
e
t
w
e
e
n
s
e
s
s
i
o
n
s
1
y
e
a
r
P
r
o
l
o
n
g
e
d
a
b
s
t
i
n
e
n
c
e
b
y
u
r
i
n
e
c
o
t
i
n
i
n
e
l
e
v
e
l
s
(
<
2
5
n
g
/
m
L
)
a
t
2
,
6
a
n
d
1
2
m
o
n
t
h
s
a
f
t
e
r
c
e
s
s
a
t
i
o
n
1
6
(
4
2
)
W
i
l
l
e
m
s
e
e
t
a
l
.
2
0
A
s
y
m
p
t
o
m
a
t
i
c
s
m
o
k
e
r
s
2
5
1
7
(
6
8
)
(
C
o
n
t
i
n
u
e
d
)
J R Soc Med Sh Rep 2011;2:78. DOI 10.1258/shorts.2011.011089
Journal of the Royal Society of Medicine Short Reports
6compared to smokers with normal lung function
(P <0.001; z= 3.93).
19
Behavioural interventions
The included Cochrane Review found that when
combined with pharmacological support, inten-
sive one-to-one counselling was better than no
treatment, or behavioural interventions on their
own, though the latter displayed a trend that
seemed to support the intervention.
11
Another small study reported high cessation
rates among COPD patients that participated in
an intensive programme based on cognitive be-
havioural therapy, compared to asymptomatic
participants.
20 One hundred percent follow-up
was achieved and biochemically-validated pro-
longed abstinence after one year was 42%.
A statistically signiﬁcant difference was found
in quit rates at three year follow-ups (38% vs.
10%, respectively; χ
2= 44.0; P< 0.0001) between
a group participating an intensive 1-year
stop-smoking programme which included a two
week period of hospitalization, compared to a
group receiving usual treatment in primary
care.
21 However, the analysis was not undertaken
on an intention-to-treat basis, and smoking preva-
lence was based on self-reports with a random
sample of quitters’ status subsequently
biochemically-veriﬁed.
A study that compared an intensiﬁed smoking
cessation programme in predominantly less
severe COPD patients to usual care, found use of
the more intense protocol doubled the quit rate
from 8.8% to 16.0% (χ
2=4.0; df =1; P =0.046),
though the odds ratio was not found to be statisti-
cally signiﬁcant.
22 However, a nested pre- and
post-test study of home-based counselling ses-
sions found 12.5% participants were classiﬁed as
abstinent at nine months, and even this is likely
to be an over-estimation since despite drop-outs,
an intention-to-treat analysis was not done and
abstinence was self-reported.
23
Similarly, a study that evaluated the effect of
providing additional nurse support (either in
one-to-one or group sessions) compared to usual
care found there was no difference in outcomes
at 12 months follow-up.
24 The lack of association
may be due to the below-power sample size,
and/or the particularly stringent outcome
measures.
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8Markers predicting quitting success
Four studies highlighted that disease severity and
smoking levels may inﬂuence patient motivation
to quit. Patients wanting to stop smoking within
one month had experienced more severe symp-
toms than those wishing to quit within six
months.
25 Nicotine dependence does not seem to
be a reliable predictor of quitting success. One
study found more nicotine-dependent quitters
were less likely to maintain abstinence to 12
months (0R = 0.83; 95% CI 0.72–0.97), as were par-
ticipants that had used NRT previously (OR =
0.48; 95% CI 0.25–0.94), another study found no
correlation between baseline nicotine dependence
score and successful smoking cessation.
13,16 By
contrast, a positive attitude towards smoking ces-
sation (OR =11.8; 95% CI 1.7–81.5) and high sali-
vary cotinine values (OR =2.1; 95% CI 1.08–3.93)
were found to be positively-correlated, signiﬁcant
predictors of continuous abstinence after one
year.
26
Smoking-related health beliefs
A qualitative study that investigated the
smoking-related health beliefs among 22 current
and ex-smokers that had experienced an acute
exacerbation in the previous year, found that
although most perceived smoking as a health
threat, almost 60% persisted.
27 It also found misin-
formation among patients: some felt a certain
tobacco consumption level was safe, or that quit-
ting was pointless as they had seen friends give
up and then die.
The studyalso found perceived barriers to quit-
ting included the feeling that smoking helped
breathing, and that it had a calming effect. Cues
to action were varied, ranging from disease sever-
ity to events external to the individual: for
example, one participant stated the realization
that she may not see her grandchildren grow up
motivated her to quit. A number of participants
reported struggling to quit or maintain their non-
smoking status.
Smokers’ motivation
One qualitative study highlighted that health pro-
fessionals should focus on the motivational level
a m o n gs m o k e r sw i s h i n gt oq u i t .
25 This study
classiﬁed 633 COPD patients into groups using the
‘Stages of Change’ model, on which the UK’s
National Health Service (NHS) smoking cessation
services are based, with those intending to quit
within: the next month (‘preparers’), the next
six but not one month (‘contemplators’); those
not intending to quit within the next six months
(‘pre-contemplators’).
28 However preparers and
contemplators differed signiﬁcantly from pre-
contemplators in a number of ways, suggesting
smoking cessation counselling should be tailored
to these two distinct groups. Pre-contemplators
were less likely to have a positive attitude to
smoking cessation than either preparers or contem-
plators (e.g. improved airways complaints or
engagement in activities of daily living as advan-
tagesassociatedwithquitting).Thepaperconcludes
pre-contemplators should be targeted with mess-
ages around the expected beneﬁts giving up.
Overall, preparers and contemplators reported
greater feelings of self-efﬁcacy than others,
though contemplators were less likely to think
they would be able to resist smoking in stressful
situations, such as feeling angry, than preparers
though they still reported signiﬁcantly greater
self-efﬁcacy than pre-contemplators. Those
motivated to quit had considered more coping
strategies (e.g. asking guests not to smoke or
making non-smoking agreements with house-
mates and colleagues). The authors recommend
this group is targeted with strategies to increase
self-efﬁcacy, and also to help develop action plan-
ning skills.
Communication with health professionals
A qualitative study of seven COPD nurses
undertaking ﬁrst counselling sessions with 30
suspected/conﬁrmed COPD patients that were
current or former smokers, found the nurses
rarely tailored the consultation to the patient’s
individual needs.
29 In addition, the majority of
the self-management education and support for
stopping smoking was given through infor-
mation, generally not with motivational dialogue
and open-ended questions that focus on a
patient’s abilities to self-manage their situation.
Four smokers were not given any smoking cessa-
tion support and only two consultations were
concluded with the development of a treatment
plan.
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9Discussion
Principal ﬁndings
The ﬁndings from this review suggest smoking
cessation services should include: a universal
early intervention to reach all smokers; encourage-
ment to report smoking status honestly; combined
psychosocial and pharmacological support; con-
frontation with spirometry; targeted health messa-
ging, segmented by patient health beliefs and
motivations; support for struggling and recent
quitters; regular appraisal and monitoring of
staff delivering services.
Guidelines state smoking status should be
queried at every patient contact.
30 Since tobacco
use is under-reported, smoking cessation should
initially address all COPD patients, to ensure infor-
mation about the beneﬁts of quitting reaches all
smokers.
23 Early ‘myth-busting’ around erroneous
beliefs (e.g. smoking makes breathing easier
should also be included).
27 Participants should
then be encouraged to admit their smoking status,
so the possibility of giving up can be explored.
Confrontation with regular spirometry tests
may help demonstrate to persistent smokers
(including those who do not admit their status)
that their lung function is declining and help
motivate patients to quit.
17–19
For those who want to quit, a combined
approach using behavioural with pharmacological
support should be offered.
11 Unlike its general
smoking cessation guidelines, where NICE rec-
ommends the doctor and patient should together
decide the most appropriate mediation support,
NICE speciﬁcally recommends the use of Bupro-
prionforCOPDpatients.
9,10Theevidencereviewed
here suggests this may have fewer side-effects than
Nortriptyline, though its efﬁcacy compared to a
placebo is not undisputed.
10,14 Buproprion also
seems to be more cost-effective.
15 Behavioural
support that helps quitters to develop self-help
strategies such as breathing techniques, may have
a role to play in supporting quitters to take
control of their anxiety and stress.
27
A smoking cessation programme should
include appropriately targeted health messages,
segmented by patient motivations and health
beliefs. Some beliefs (e.g. denying the link
between smoking and disease progression) could
be addressed both at campaign and individual
counselling levels. By contrast, categorizing
patients according to Stage of Change would
allow interventions to be tailored more closely to
each individual’s readiness to quit.
25 For
example, pre-contemplators are less likely to
have a positive attitude to giving up and should
be targeted with messages around the beneﬁts of
quitting. Messaging could also tap into social
cues relevant to a particular patient.
27
All staff delivering smoking cessation advice
should be adequately trained and routinely
appraised and monitored to ensure service
quality and standards.
29 Health professionals
need to provide accurate, understandable infor-
mation and delivery of stop-smoking messages
should use open questions, and focus on motiva-
tional dialogue to assess and support a patient’s
ability to self-manage their situation.
27,29
Support for recent and/or struggling quitters
who may not be able to maintain their smoke-free
status, for example by scheduling regular checks
at, for example, three, six and 12 months post
quit date. In addition, focusing on strategies for
promoting self-efﬁcacy, dealing with anxiety and
self-management of the disease may be helpful.
27
Although a literature review of the family’s role
in supporting COPD patientsto quit was inconclu-
sive about the effectiveness of family-oriented
stop smoking interventions, participants in
studies reviewed here have cited lack of support
from relatives as a barrier to smoking cessation,
with those intending to quit within six months
receiving more social support.
25,27,31 One study
placed smoking cessation sessions in patients’
homes to allow counsellors could get a better
understanding of the social barriers to quitting
their clients were facing, though the study did
not go on to assess the impact of this measure.
23
Similarly, COPD patients participating in residen-
tial smoking cessation programme were hospital-
ized with their spouses, though again the
authors do not comment or explore this further.
21
Strengths and weaknesses of this study
Strengths of this study include the: precision of the
search strategy; selection of abstracts was under-
taken by MR and SCC; systematic appraisal of
papers using established frameworks and
scoring methods; inclusion of qualitative research
to understand patient barriers to smoking
cessation.
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10Ideally, appraising the full-text papers should
have been done by at least two independent
scorers. A lack of time and ﬁnancial resources
did not allow for this. Possible bias was kept to a
minimum by rigorously following a deﬁned criti-
cal appraisal checklist and by using a well-known,
independent scoring system.
The search criteria were set to only include
studies from north-western Europe as these
countries have primary care systems most
similar to the UK. Only three studies from the
UK were identiﬁed that met the inclusion criteria,
suggesting there is a gap in the literature, and
more research is needed.
Strengths and weaknesses in relation
to other studies
Study heterogeneity made it difﬁcult to draw com-
parisons. Differing end-points, both in terms of
type (carbon monoxide vs. urinary cotinine) and
level (urinary cotinine <60 ng/mL vs. <25 ng/
mL), and method of measurement (self-report
vs. biochemical validation) and outcomes (5 vs.
52 weeks abstinence) mean inter-study compar-
ability is limited.
By not analysing results on an intention-to-treat
basis, some studies may have overestimated the
effect size.
21,23 By contrast, a number of studies
that found no effect were under-powered,
meaning a true effect could have been
masked.
18,24 Evidence for behavioural interven-
tions, including intervention type and effective-
ness, was less clear. As blinding is almost
impossible in these studies, the lack of signiﬁcant
ﬁndings could be due to contamination between
intervention and control groups.
The main risk factor for COPD, smoking, is also
associated with other serious health conditions,
but most of the reviewed studies excluded
people with other signiﬁcant conditions such as
those with ‘severe co-morbidities’, or alcohol
dependence issues.
21,24 The evidence identiﬁed
in this review may therefore not be generalisable
to all COPD patients.
What this study contributes
Despite COPD being a major public health
problem, this review found a lack of high-quality
evidence for effective smoking cessation interven-
tions for these patients. As such this review cannot
recommend interventions that would deﬁnitely
lead to increased quit rates. However, this study
contributes an increased understanding of which
interventions could improve smoking cessation
rates, and highlights some of the barriers to quit-
ting felt by patients.
Future research
Given the public health signiﬁcance of COPD, it is
surprising there is not more evidence for effective
smoking cessation interventions in this group.
Areas for future research include: effectiveness of
pharmacological interventions; efﬁcacy of psycho-
social interventions; understanding the role of
family; and the collection of more qualitative evi-
dence around (perceived) barriers to quitting.
Conclusion
The ﬁndings from this review suggest how
smoking cessation support for COPD patients
could be improved to increase quit rates. In
addition, areas that would beneﬁt from further
research are highlighted.
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